yellow fever
Information
- Disease name
- yellow fever
- Disease ID
- DOID:9682
- Description
- "A viral infectious disease that results in infection, has_material_basis_in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood." [url:http\://en.wikipedia.org/wiki/Yellow_fever, url:http\://www.who.int/mediacentre/factsheets/fs100/en/index.html, url:https\://www.cdc.gov/yellowfever/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05011123 | Active, not recruiting | Phase 2 | Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia | October 7, 2021 | April 23, 2027 |
| NCT04269265 | Active, not recruiting | Phase 1/Phase 2 | The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination | July 1, 2020 | June 30, 2025 |
| NCT00982137 | Completed | Phase 2 | Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) | July 2004 | March 2007 |
| NCT01426243 | Completed | Phase 3 | The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. | July 2011 | December 2017 |
| NCT01436396 | Completed | Phase 3 | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers | September 7, 2011 | September 2, 2013 |
| NCT01466387 | Completed | Phase 3 | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults | November 2011 | April 2012 |
| NCT01488890 | Completed | Phase 2 | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine | December 6, 2011 | September 27, 2013 |
| NCT01943305 | Completed | Phase 2 | The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans | October 2013 | December 2015 |
| NCT02572518 | Completed | Immunity After Two Doses of Yellow Fever Vaccine | May 2014 | July 2015 | |
| NCT02743455 | Completed | Phase 1 | A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers | July 5, 2016 | March 22, 2018 |
| NCT00616356 | Completed | Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults | December 2007 | June 2008 | |
| NCT02991495 | Completed | Phase 4 | Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) | November 6, 2017 | December 31, 2021 |
| NCT03116802 | Completed | Phase 2 | Yellow Fever Vaccine on Statin/ Non Statin Subjects | March 8, 2017 | April 16, 2018 |
| NCT03541694 | Completed | Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea | April 11, 2018 | May 30, 2018 | |
| NCT05172544 | Completed | Phase 1 | Trial of an Inactivated Yellow Fever Virus Vaccine | January 13, 2022 | April 24, 2023 |
| NCT00995865 | Completed | Phase 1 | Trial of Yellow Fever Inactivated Vaccine | January 2010 | October 2010 |
| NCT04059471 | Completed | Phase 4 | Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine | November 11, 2019 | June 24, 2023 |
| NCT04267809 | Completed | Phase 2 | Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection | October 22, 2021 | July 31, 2023 |
| NCT03870061 | Completed | N/A | Evaluation of an Infant Immunization Encouragement Program in Nigeria | July 1, 2018 | February 20, 2020 |
| NCT05644145 | Enrolling by invitation | N/A | Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina | December 6, 2022 | July 30, 2023 |
| NCT05450770 | Not yet recruiting | N/A | Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination | January 1, 2024 | November 1, 2024 |
| NCT05901454 | Recruiting | N/A | Yellow Fever Human Infection Model With YF-17D | February 17, 2023 | March 1, 2024 |
| NCT00694655 | Recruiting | Phase 4 | Human Immune Responses to Yellow Fever Vaccination | May 2008 | December 31, 2025 |
| NCT01290055 | Recruiting | Phase 4 | Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine | February 2011 | June 2024 |
| NCT05421611 | Recruiting | Phase 3 | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL | May 11, 2023 | May 10, 2024 |
| NCT05447377 | Recruiting | Phase 3 | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants | September 16, 2022 | January 30, 2024 |
| NCT05568953 | Recruiting | Phase 2 | An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity | September 28, 2022 | October 2025 |
| NCT05859490 | Recruiting | Phase 1/Phase 2 | Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination | August 1, 2023 | December 31, 2024 |
| NCT03891420 | Terminated | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | April 9, 2020 | April 30, 2021 |
| NCT04235361 | Unknown status | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC | January 15, 2021 | July 30, 2021 | |
| NCT05332197 | Unknown status | Phase 3 | Booster Vaccine for Yellow Fever | May 16, 2022 | September 2023 |
| NCT02990182 | Unknown status | Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children | April 2015 | December 2017 | |
| NCT03725618 | Unknown status | Phase 4 | Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old | November 2018 | September 2020 |
- Disase is a (Disease Ontology)
- DOID:934
- Cross Reference ID (Disease Ontology)
- GARD:7914
- Cross Reference ID (Disease Ontology)
- ICD10CM:A95
- Cross Reference ID (Disease Ontology)
- ICD9CM:060
- Cross Reference ID (Disease Ontology)
- MESH:D015004
- Cross Reference ID (Disease Ontology)
- NCI:C35547
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154345006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0043395
- Exact Synonym (Disease Ontology)
- jungle yellow fever
- Exact Synonym (Disease Ontology)
- Sylvatic yellow fever
- Exact Synonym (Disease Ontology)
- urban yellow fever
- Exact Synonym (Disease Ontology)
- Yellow fever, sylvan
- OrphaNumber from OrphaNet (Orphanet)
- 99829
- ICD10 preferred id (Insert disease from ICD10)
- D0000452
- ICD10 class code (Insert disease from ICD10)
- A95
- MeSH unique ID (MeSH (Medical Subject Headings))
- D015004